NBIX CFO reports charitable stock gift of shares

Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported a charitable stock gift.

Rhea-AI Filing Summary

Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported a charitable stock gift. On March 4, 2026, he transferred 2,249 shares of Neurocrine Biosciences common stock as a bona fide gift, with no value received and no market transaction involved.

After this disposition, he directly holds 42,808 shares of common stock, which include 176 shares purchased on February 27, 2026 under the company’s 2018 Employee Stock Purchase Plan.

Insider Trade Summary

2,249 shares gifted

Gift 1 txn

Insider ABERNETHY MATT

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	2,249	$0.00	$0.00

Holdings After Transaction: Common Stock — 42,808 shares (Direct)

Footnotes (2)

1. F1. This transaction represents a gift/charitable contribution effective March 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.
2. F2. Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NBIX’s CFO report on this Form 4?

NBIX’s Chief Financial Officer Matt Abernethy reported a bona fide gift of 2,249 shares of common stock. The transfer was effective March 4, 2026 and is described as a charitable contribution rather than a market-based stock sale.

Did the NBIX CFO receive any value for the 2,249 gifted shares?

No, the filing states that no value was received for the 2,249 gifted shares. It characterizes the transfer as a gift or charitable contribution and clarifies that it was not executed as a market transaction in the company’s stock.

How many NBIX shares does the CFO hold after this gift transaction?

Following the gift of 2,249 shares, the CFO directly holds 42,808 shares of Neurocrine Biosciences common stock. This post-transaction balance includes 176 shares purchased through the company’s 2018 Employee Stock Purchase Plan on February 27, 2026.

What does the Form 4 say about the nature of the NBIX stock transaction?

The Form 4 describes the transaction as a bona fide gift coded as “G.” A footnote explains it represents a gift or charitable contribution effective March 4, 2026 and confirms it is not a market transaction in Neurocrine Biosciences common stock.

Are any Employee Stock Purchase Plan shares mentioned in this NBIX filing?

Yes. A footnote notes that the CFO’s holdings include 176 shares purchased on February 27, 2026 under the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, and these shares are part of the reported post-transaction ownership total.

Does this NBIX Form 4 indicate a market sale of shares by the CFO?

No, the filing explicitly states the transaction is not a market transaction. It is characterized as a gift or charitable contribution, with no price reported and no value received, distinguishing it from an open-market stock sale by the executive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 06:18 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABERNETHY MATT

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		G(1)		2,249	D	$0	42,808(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective March 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

2. Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.